| Literature DB >> 36061660 |
Afia Saleem1, Umar Farooq1, Syed Majid Bukhari1, Sara Khan1, Asma Zaidi1, Tanveer A Wani2, Ahson Jabbar Shaikh1, Rizwana Sarwar1, Shafi Mahmud3, Muhammad Israr4, Farhan A Khan1, Sohail Anjum Shahzad1.
Abstract
Heterocyclic compounds with a five-membered ring as a core, particularly those containing more than one heteroatom, have a wide spectrum of biological functions, especially in enzyme inhibition. In this study, we present the synthesis of five-membered heterocyclic isoxazole derivatives via sonication of ethyl butyrylacetate with aromatic aldehyde in the presence of a SnII-Mont K10 catalyst. The synthesized compounds were characterized using sophisticated spectroscopic methods. In vitro testing of the compounds reveals three derivatives with significant inhibitory action against carbonic anhydrase (CA) enzyme. The compound AC2 revealed the most promising inhibitory activity against CA among the entire series, with an IC50 = 112.3 ± 1.6 μM (%inh = 79.5) followed by AC3 with an IC50 = 228.4 ± 2.3 μM (%inh = 68.7) compared to the standard with 18.6 ± 0.5 μM (%inh = 87.0). Molecular docking (MD) study coupled with extensive MD simulations (400 ns) and MMPBSA study fully supported the in vitro enzyme inhibition results, evident from the computed ΔG bind (AC2 = -13.53 and AC3 = -12.49 kcal/mol). The in vitro and in silico studies are also augmented by a fluorescence-based enzymatic assay in which compounds AC2 and AC3 showed significant fluorescence enhancement. Therefore, on the basis of the present study, it is inferred that AC2 and AC3 may serve as a new framework for designing effective CA inhibitors.Entities:
Year: 2022 PMID: 36061660 PMCID: PMC9434621 DOI: 10.1021/acsomega.2c03600
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Derivative of Isoxazole.
Scheme 1Synthesis of the Catalyst
Scheme 2Synthesis of (E)-4-(Arylmethylene)-3-propylisoxazol-5(4H)-one Derivatives
Docking Results for Isoxazole Derivatives against CA Protein as Well as Per-residue Contribution Factor Estimated from 2D and 3D Interaction Patterns
| compound IDs/name | binding energy | H-bond | van der Waals | hydrophobic interaction |
|---|---|---|---|---|
| AC1 | –15.9467 | His119,His94 | Phe94, His94/98, Leu198, Thr199 | Ala121, Leu141, Val143, Trp209 |
| AC2 | –15.0785 | Thr199, His119 | His94/96/119, Leu198, His200 | Ala121, Leu141, Val143 |
| AC3 | –13.9565 | His119, Thr199 | His94/96/200, Leu198 | Phe191, Ala121, Val143, Trp209 |
| AC4 | –13.436 | His94, His119 | Phe91, His94, Leu198, | Ala121, Val143, Leu141, Trp209 |
| AC5 | –13.3782 | His119 | His94, His200, Leu198 | Trp209, Val143, Phe91, Ala121 |
| AC6 | –13.0815 | Thr199, His 200 | His94, Leu198 | Leu198 |
| AC7 | –10.8149 | Tyr7, Asp8, His243 | Ser231, Gly216, Asp8 | no interaction |
| AC8 | –9.95393 | Thr199 | His94/119/200/Leu198 | Leu198, Trp209 |
| AC9 | –9.72169 | Thr199 | His94/200 | Leu198, Trp209 |
| AC10 | –9.12506 | His119/200, Thr199 | His94/200, Leu198 | Leu198, Trp209 |
Figure 2Graphical representation of % inhibition of all compounds (1–10) compared against the standard.
Structures along with In Vitro Carbonic Anhydrase Inhibition Potential of Compounds 1–10
Figure 3(a) RMSD vs time plot for the CA obtained from the 100 ns MD simulations in its corresponding ligand-bound and free state. (b) Protein flexibility for individual residues as inferred by RMSF for bound (AC1 = blue, AC2 = green, AC3 = purple) and free CA (red). (c) Contribution of key residues to protein ligand binding in terms of energy. (All values are given in kcal/mol). (d) 2D interaction diagrams for CA-binding site with AC1–AC3. The three-letter amino acid code is assigned to each residue. The distance between hydrogen bonds is shown as a dotted line in angstroms.
Binding Free Energy Analysis (MMPBSA) of Protein–Ligand Complexes (kcal/mol)a
| Comp. IDs | Δ | Δ | Δ | PB-SOL (polar + np) | PB(total) (kcal/mol) | –TS | Δ |
|---|---|---|---|---|---|---|---|
| AC1 | –6.04 | –25.12 | –31.16 | 12.52 | –18.64 | 7.21 | –11.43 |
| AC2 | –7.27 | –25.28 | –32.55 | 10.18 | –22.37 | 8.84 | –13.53 |
| AC3 | –6.21 | –23.32 | –29.53 | 10.12 | –19.41 | 6.92 | –12.49 |
ΔEelec = electrostatic energy computed using the MM force field, ΔEvdw = van der Waals contribution, GAS = total gas phase energy, PB-SOL = polar and nonpolar contributions to solvation, TS = entropy, ΔGPB = free energy of binding with entropy.
Figure 4Fluorescence intensities of compounds AC2 and AC3 before (blue) and after (red) complex formation with CA-. In panels (a) and (b), the compounds 2 (AC2)and 3 (AC3), respectively, represent more enhancement in the fluorescence signal. In panel (c), negligible enhancement in the fluorescence signal of compound 6 (AC1) is shown. Panel4 d shows fluorescence enhancement of the standard drug.